Karolinska Development (B) Aktie

0,0620 EUR -0,0125 EUR -16,78 %

08:11:25

STU

0,8950 SEK ±0,0000 SEK ±0,00 %

24.09.2025

STO

Karolinska Development (B) jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.21,90 Mio. EUR

Div. Rendite0,00%

WKNA0M84G

ISINSE0002190926

SymbolKDEVF

Karolinska Development (B) Aktien News

Sortieren:Datum Meistgelesen

04.06.25GlobeNewswireKarolinska Development’s portfolio company OssDsign raises approximately SEK 158 million, announces an updated strategy and revises financial targets

26.05.25GlobeNewswireKarolinska Development’s portfolio company Umecrine Cognition resumes patient inclusion in its Phase 1b/2a clinical study

15.05.25GlobeNewswireKarolinska Development’s Annual General Meeting 2025

WerbungKarolinska Development (B)-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

13.05.25GlobeNewswireKarolinska Development’s portfolio company OssDsign has treated 10,000 patients with OssDsign Catalyst in the US

07.05.25GlobeNewswireKarolinska Development’s portfolio company Umecrine Cognition presents data validating novel clinical scale in PBC at EASL 2025

05.05.25GlobeNewswireKarolinska Development’s portfolio company Umecrine Cognition receives grant from The Michael J. Fox Foundation

30.04.25GlobeNewswireKarolinska Development portfolio company OssDsign will change CEO during second half of 2025

30.04.25GlobeNewswireInterim Report - January-March 2025

07.04.25GlobeNewswireNotice of Annual General Meeting in Karolinska Development AB (publ)

01.04.25GlobeNewswireKarolinska Development’s portfolio company Umecrine Cognition appoints new CEO

01.04.25GlobeNewswireKarolinska Development’s portfolio company Umecrine Cognition presents promising preclinical Parkinson data at AD/PD 2025

21.03.25GlobeNewswireKarolinska Development Annual Report 2024 published

18.03.25GlobeNewswireKarolinska Development’s portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study

13.03.25GlobeNewswireKarolinska Development’s portfolio company AnaCardio has been granted additional EU patent for drug candidate AC01

12.03.25GlobeNewswireKarolinska Development's portfolio company PharmNovo receives positive FDA feedback prior to IND application for Phase 2a trial

25.02.25GlobeNewswireKarolinska Development’s portfolio company AnaCardio includes first patient in a phase 2a study of its drug candidate AC01

18.02.25GlobeNewswireKarolinska Developments portfolio company Promimic publishes positive results on reduction of bacteria growth on HAnano Surface

14.02.25GlobeNewswireYear-end Report - January-December 2024

30.01.25GlobeNewswireKarolinska Development’s portfolio company Dilafor advances tafoxiparin following successful meetings with FDA and European regulatory authorities

09.01.25GlobeNewswireKarolinska Development’s portfolio company AnaCardio raises SEK 205 million and reports positive Phase 1b data of AC01

19.12.24GlobeNewswireKarolinska Development’s portfolio company Umecrine Cognition raises MSEK 23.8 to continue clinical development of golexanolone

18.12.24GlobeNewswireKarolinska Development’s Board of Directors appoints Ben Toogood as new Chairman

11.12.24GlobeNewswireKarolinska Development’s Chairman of the Board resigns at his own request

10.12.24GlobeNewswireKarolinska Development divests 4,6 million shares in portfolio company OssDsign

09.12.24GlobeNewswireKarolinska Development's portfolio company Modus Therapeutics initiates a phase 2 study with sevuparin for treatment of chronic kidney disease with anemia

02.12.24GlobeNewswireKarolinska Development implements organizational changes for more efficient portfolio management

19.11.24GlobeNewswireKarolinska Development's portfolio company Modus Therapeutics secures bridge financing

18.11.24GlobeNewswireKarolinska Development’s portfolio company Umecrine Cognition presents positive interim data from Phase 1b/2a clinical study

15.11.24GlobeNewswireKarolinska Development's portfolio company SVF Vaccines appoints Dr Gaston Picchio as acting CEO

15.11.24GlobeNewswireInterim Report - January-September 2024

13.11.24GlobeNewswireKarolinska Development’s Extraordinary General Meeting 2024

05.11.24GlobeNewswireKarolinska Development’s portfolio company BOOST Pharma successfully completes pre-IND meeting with FDA and receives second tranche of investment

21.10.24GlobeNewswireKarolinska Development’s portfolio company SVF Vaccines announces positive data from a phase 1 study of its universal Covid-19 vaccine

17.10.24GlobeNewswireKarolinska Development’s portfolio company Umecrine Cognition presents new preclinical Parkinson’s data on golexanolone at the scientific conference, INBC 2024

15.10.24GlobeNewswireNotice of Extraordinary General Meeting in Karolinska Development AB (publ)

23.09.24GlobeNewswireKarolinska Development divests its holding in the Danish dermatology company Henlez

17.09.24GlobeNewswireKarolinska Development’s portfolio company AnaCardio reports progress in two clinical trials with its drug candidate AC01

17.09.24GlobeNewswireKarolinska Developments portfolio company BOOST Pharma announces positive top-line results from a Phase 1/2 study with over 75% reduction of fracture rates in children with rare bone disease

30.08.24GlobeNewswireKarolinska Development’s portfolio company Biosergen announces successful treatment of first patient in a clinical trial of BSG005

30.08.24GlobeNewswireInterim Report - January-June 2024

Karolinska Development (B) News

Karolinska Development (B) News: auf dieser Seite finden Sie alle Karolinska Development (B) News und Nachrichten zur Karolinska Development (B) Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Karolinska Development (B) News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Karolinska Development (B) News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.